TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12924045

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (50 to 60 Gy of radiotherapy plus concurrent chemotherapy with 5-fluorouracil (5-FU) plus cisplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy and chemotherapy with 5-FU plus cisplatin
Number of subjects: 0
Study: 10229251

Group type: EXPERIMENTAL
Intervention: Combination of a light breakfast and 2 phosphate enemas
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Additional preparatory measures (dietary restrictions and phospho-soda oral saline laxative)
Number of subjects: 429
Study: 8735074

Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation (CAS) with contralateral broadband noise (BBN)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No contralateral acoustic stimulation (CAS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation (CAS)
Number of subjects: 64
Study: 1867076

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg body weight infused over 5 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study: 7048913

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30787276

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 20
Study: 27619750

Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg, monthly subcutaneous)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 905
Study: 27053444

Group type: EXPERIMENTAL
Intervention: Standard primary PCI with immediate stent implantation
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Deferred stent implantation
Number of subjects: 1215
Study: 25251888

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 326
Study: 21913027

Group type: EXPERIMENTAL
Intervention: Sodium-bicarbonated mineral water (BW) with a standard meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium-bicarbonated mineral water (BW) without a meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low mineral content water (CW) with a standard meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low mineral content water (CW) without a meal
Number of subjects: 0
Study: 19507295

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Montessori-based activities
Number of subjects: 133

Group type: COMPARATOR
Intervention: Presence (control group)
Number of subjects: 133
Study: 17475133

Group type: EXPERIMENTAL
Intervention: Covered toes with a sterile glove
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncovered toes
Number of subjects: 40
Study: 15341545

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 17163298

Group type: EXPERIMENTAL
Intervention: Metoclopramide 5mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 2.5mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 11110009

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, 100 mg, or 200 mg)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 9162222

Group type: EXPERIMENTAL
Intervention: GM-CSF plus IFN-alpha
Number of subjects: 20

Group type: COMPARATOR
Intervention: IFN-alpha alone
Number of subjects: 20
Study: 1363700

Group type: EXPERIMENTAL
Intervention: poly‐saccharide sulphate (PSS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: DX40
Number of subjects: 30
Study: 6373033

Group type: EXPERIMENTAL
Intervention: Oral anticholera vaccine
Number of subjects: 36640

Group type: EXPERIMENTAL
Intervention: Injected anticholera vaccine
Number of subjects: 36640

Group type: COMPARATOR
Intervention: Non-inoculated group
Number of subjects: 36640
Study: 28952858

Group type: EXPERIMENTAL
Intervention: Aerobic exercise protocol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4
Study: 29316845

Group type: EXPERIMENTAL
Intervention: VX-210
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28262195

Group type: EXPERIMENTAL
Intervention: Conventional heart failure treatment combined with an individualized nutritional intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional heart failure treatment
Number of subjects: 120
Study: 24484452

Group type: EXPERIMENTAL
Intervention: Everolimus with prednisolone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (RTR without pulmonary symptoms)
Number of subjects: 102
Study: 22065156

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 20921038

Group type: EXPERIMENTAL
Intervention: Diabetes Manual programme (one-to-one structured educational intervention)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diabetes Manual programme
Number of subjects: 12
Study: 17137836

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Passive head movement
Number of subjects: 24
Study: 15831419

Group type: EXPERIMENTAL
Intervention: Spherical harmonics (SH) method for approximating 3D shape and estimating volume of brain tumors
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spherical harmonics (SH) method
Number of subjects: 5
Study: 11888098

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 0.5mg/kg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10028201

Group type: EXPERIMENTAL
Intervention: Exposure to PAHs
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Exposure to asbestos
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Patients with overt cancer
Number of subjects: 235

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 235
Study: 7626370

Group type: EXPERIMENTAL
Intervention: Zamic (ZA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Arginine aspartate (AA)
Number of subjects: 24
Study: 31830787

Group type: EXPERIMENTAL
Intervention: Coherent superposition of Fermi resonant eigenstates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy gaps (Δν̃) of eigenstates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dephasing rate
Number of subjects: 0
Study: 31209667

Group type: EXPERIMENTAL
Intervention: Microsatellite stable (MSS) patients
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: MSI patients
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: MSS population with RAS or BRAF mutations
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Recurrence in peritoneum or more than two recurrence sites
Number of subjects: 1650
Study: 28028768

Group type: EXPERIMENTAL
Intervention: Betaine HCl (1500 mg) after rabeprazole pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rabeprazole (20 mg twice daily)
Number of subjects: 0
Study: 26589718

Group type: EXPERIMENTAL
Intervention: Early stoma closure (8-10 days after resection, before starting adjuvant therapy)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Late stoma closure (26 weeks after resection and completion of adjuvant therapy)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Stoma-related complications
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Individual completeness of chemotherapy rate
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Percentage of patients stopping adjuvant therapy or undergoing dose modifications or delay
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Oncological outcomes
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Cumulative days of hospitalisation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Number of readmissions
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Rate of symptomatic anastomotic leaks after stoma closure
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Post-operative complications
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Toxicity of adjuvant chemotherapy
Number of subjects: 257
Study: 22816533

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21355155

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with Amitriptyline
Number of subjects: 86

Group type: COMPARATOR
Intervention: Indomethacin combined with Amitriptyline
Number of subjects: 86
Study: 19389718

Group type: EXPERIMENTAL
Intervention: Unilateral temporal lobe resection (either temporal lobectomy, selective amygdalohippocampectomy or lesionectomy)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postoperative functional activation in the right mesial temporal lobe
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postoperative functional activation in the left mesial temporal lobe
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postoperative memory performance
Number of subjects: 17
Study: 16760874

Group type: EXPERIMENTAL
Intervention: Radioguided surgery (scinti-probe technique)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Computed tomography-guided hookwire localization
Number of subjects: 30
Study: 15130206

Group type: EXPERIMENTAL
Intervention: Experiential learning intervention (integrated, end-of-life clinical pathway: PEACE Tool)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 54
Study: 11420161

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 9413374

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 67
Study: 8103013

Group type: EXPERIMENTAL
Intervention: Octreotide at 3 x 100 micrograms/day subcutaneously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3613879

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 154
Study: 29413370

Group type: EXPERIMENTAL
Intervention: Supervised center-based exercise training (ET) for 24 weeks
Number of subjects: 278

Group type: COMPARATOR
Intervention: Supported home exercise program (control)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Participants who exercised to guidelines (intervention)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Participants who exercised to guidelines (control)
Number of subjects: 278
Study: 27216479

Group type: EXPERIMENTAL
Intervention: Aluminium triformate mouthrinse (ATF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 40
Study: 24112601

Group type: EXPERIMENTAL
Intervention: Ankle bracing
Number of subjects: 15

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 15
Study: 23080059

Group type: EXPERIMENTAL
Intervention: lotrafilcon B, CIBA Vision
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: omafilcon A, CooperVision
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: hydrogen peroxide care system (Clear Care, CIBAVision)
Number of subjects: 446

Group type: COMPARATOR
Intervention: none
Number of subjects: 446
Study: 20467406

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections (average molecular weight 1.5 million Da), 3 injections at weeks 1, 2, and 3
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (0.9% saline), 3 injections at weeks 1, 2, and 3
Number of subjects: 48
Study: 18384679

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16005691

Group type: EXPERIMENTAL
Intervention: Carvedilol test formulation from Laboratórios Biosintética Ltda
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coreg from Roche Químicos e Farmacêuticos S.A standard reference formulation
Number of subjects: 0
Study: 12698397

Group type: EXPERIMENTAL
Intervention: UFH-based strategy with AT III
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UFH-based strategy with r-hirudin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UFH-based strategy with tirofiban
Number of subjects: 100

Group type: COMPARATOR
Intervention: ACT management
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UFH-based strategy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UFH-based strategy with AT III, r-hirudin, or tirofiban
Number of subjects: 100
Study: 10488513

Group type: EXPERIMENTAL
Intervention: Surgical discectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard discectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microdiscectomy and standard discectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interposition membrane after discectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Instrumented fusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Noninstrumented fusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical decompression or fusion for degenerative lumbar spondylosis
Number of subjects: 40
Study: 8724711

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using expanded polytetrafluoroethylene (ePTFE) membranes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Routine home care with daily chlorhexidine rinse and systemic tetracycline
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sites with minimal or no plaque (plaque index [PI] <= 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sites with no Actinobacillus actinomycetemcomitans
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sites with Porphyromonas gingivalis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pi-infected sites
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall treatment with membrane barriers
Number of subjects: 28
Study: 1720828

Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (10‐min infusion, doses ranging from 0.001 to 1 mg/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (100, 600, or 1,200 mg p.o.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (1,200 mg p.o.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ro 42‐5892
Number of subjects: 38
Study: 6758833

Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg daily given orally for two weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31464286

Group type: EXPERIMENTAL
Intervention: Recognan (citicoline) 500 mg (5 ml) orally for 30 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: No drug therapy (Control)
Number of subjects: 38
Study: 30255345

Group type: EXPERIMENTAL
Intervention: Running locked 3-0 delayed absorbable suture (Group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Extracorporeal interrupted 3-0 delayed absorbable sutures (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 26651260

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg qd
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 24216721

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day) and cilostazol (200 mg/day) with behavioral modifications
Number of subjects: 34

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day) with behavioral modifications (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Probucol and cilostazol treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 34
Study: 22898703

Group type: EXPERIMENTAL
Intervention: 48 weeks of pegylated interferon plus ribavirin (n=168)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: 72 weeks of pegylated interferon plus ribavirin (n=167)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Comparison of 72-week vs 48-week treatment in non-week-8 viral response patients
Number of subjects: 335
Study: 20052732

Group type: EXPERIMENTAL
Intervention: Group Education
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: One-on-one education
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Reducing out-of-pocket costs
Number of subjects: 369
Study: 17392464

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: No patch (matched nonsmokers)
Number of subjects: 0
Study: 15971426

Group type: EXPERIMENTAL
Intervention: Air-steroid-saline mixture as contrast medium
Number of subjects: 0
Study: 12410357

Group type: EXPERIMENTAL
Intervention: Carotid eversion endarterectomy (CEE)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Traditional CEA with patching (CEAP)
Number of subjects: 310
Study: 10637949

Group type: EXPERIMENTAL
Intervention: Randomised treatment within 3 hours
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Randomised treatment within 6 hours
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Death or dependency at 6 months
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Total anterior circulation infarcts
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Lacunar strokes
Number of subjects: 1631
Study: 7737560

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg daily for one week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2036277

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lornoxicam 2 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 7131544

Group type: EXPERIMENTAL
Intervention: High feedback ultrasound (N = 67)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Low feedback ultrasound (N = 62)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 129
Study: 29982720

Group type: EXPERIMENTAL
Intervention: Treatment adjustment not in agreement with TTT strategy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Elevated disease activity measure despite no objective evidence of active RA
Number of subjects: 74
Study: 26642907

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided warfarin dosing algorithm
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Clinically-guided warfarin dosing algorithm
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Both arms (pharmacogenetic and clinical)
Number of subjects: 1015
Study: 25685772

Group type: EXPERIMENTAL
Intervention: Prophylaxis and counseling to adhere to it
Number of subjects: 341
Study: 23006426

Group type: EXPERIMENTAL
Intervention: ACTIVE memory training intervention
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 1401
Study: 20950379

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 5269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5269
Study: 18181162

Group type: EXPERIMENTAL
Intervention: Radioguided occult lesion localization (ROLL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 100
Study: 16804099

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Codeine phosphate 7‐15 mg 3‐4 times daily
Number of subjects: 15
Study: 12631126

Group type: EXPERIMENTAL
Intervention: Eprosartan (E) 600 mg/day PO for seven days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Eprosartan (E)
Number of subjects: 24
Study: 10672218

Group type: EXPERIMENTAL
Intervention: Continuous retraction force averaging 18 g
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous retraction force averaging 60 g
Number of subjects: 7
Study: 9032777

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg/h cortisol infusion
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg/h cortisol infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo condition (placebo tablets and normal saline infusion)
Number of subjects: 32
Study: 8195849

Group type: EXPERIMENTAL
Intervention: brodimoprim
Number of subjects: 74

Group type: COMPARATOR
Intervention: roxithromycin
Number of subjects: 74
Study: 3896283

Group type: EXPERIMENTAL
Intervention: Nicardipine (5 mg h-1 for 3 h via intravenous infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg three times daily for 1 week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control group in the second study)
Number of subjects: 12
Study: 30087193

Group type: EXPERIMENTAL
Intervention: Large spacer plus pMDI (pressurized metered-dose inhaler)
Number of subjects: 12

Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 12

Group type: COMPARATOR
Intervention: Large spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Large spacer plus pMDI
Number of subjects: 12
Study: 27687343

Group type: COMPARATOR
Intervention: High dose of remifentanil (HR) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low dose of remifentanil (LR) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Butorphanol combined with remifentanil (BR) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low dose of butorphanol (BR group)
Number of subjects: 75
Study: 24048161

Group type: EXPERIMENTAL
Intervention: SMOFlipid emulsion for 7 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clinoleic emulsion for 7 days
Number of subjects: 34
Study: 23698697

Group type: EXPERIMENTAL
Intervention: Brief counseling session on alcohol risk reduction
Number of subjects: 147

Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 147